DK1146864T3 - pH-uafhængig farmaceutisk formulering med forlænget frisætning - Google Patents

pH-uafhængig farmaceutisk formulering med forlænget frisætning

Info

Publication number
DK1146864T3
DK1146864T3 DK00904586T DK00904586T DK1146864T3 DK 1146864 T3 DK1146864 T3 DK 1146864T3 DK 00904586 T DK00904586 T DK 00904586T DK 00904586 T DK00904586 T DK 00904586T DK 1146864 T3 DK1146864 T3 DK 1146864T3
Authority
DK
Denmark
Prior art keywords
weight percent
tablet
release
extended
pharmaceutical formulation
Prior art date
Application number
DK00904586T
Other languages
Danish (da)
English (en)
Inventor
Kevin R Engh
Yihong Qiu
Venkatramana Rao
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK1146864T3 publication Critical patent/DK1146864T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00904586T 1999-02-04 2000-01-26 pH-uafhængig farmaceutisk formulering med forlænget frisætning DK1146864T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24467899A 1999-02-04 1999-02-04
PCT/US2000/001954 WO2000045793A1 (en) 1999-02-04 2000-01-26 Ph independent extended release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
DK1146864T3 true DK1146864T3 (da) 2009-05-11

Family

ID=22923698

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904586T DK1146864T3 (da) 1999-02-04 2000-01-26 pH-uafhængig farmaceutisk formulering med forlænget frisætning

Country Status (10)

Country Link
EP (1) EP1146864B1 (enExample)
JP (2) JP5420126B2 (enExample)
AT (1) ATE424191T1 (enExample)
CA (1) CA2361496C (enExample)
CY (1) CY1108863T1 (enExample)
DE (1) DE60041691D1 (enExample)
DK (1) DK1146864T3 (enExample)
ES (1) ES2321908T3 (enExample)
PT (1) PT1146864E (enExample)
WO (1) WO2000045793A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US20020025341A1 (en) * 1998-12-18 2002-02-28 Yihong Qiu Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2002051402A1 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
CN107811985B (zh) * 2016-09-13 2021-05-28 四川科瑞德制药股份有限公司 一种抗癫痫缓释制剂及其制备方法与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3809764A1 (de) * 1988-03-23 1989-10-05 Knoll Ag Mischung aus alginaten und polyacrylaten und deren verwendung
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU6824996A (en) * 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
CA2254078A1 (en) * 1997-03-11 1998-09-17 Hexal Ag Solid, non-deliquescent formulations of sodium valproate

Also Published As

Publication number Publication date
EP1146864A1 (en) 2001-10-24
JP5420590B2 (ja) 2014-02-19
CY1108863T1 (el) 2014-07-02
JP5420126B2 (ja) 2014-02-19
WO2000045793A1 (en) 2000-08-10
CA2361496C (en) 2011-06-07
JP2011241218A (ja) 2011-12-01
JP2002536318A (ja) 2002-10-29
ATE424191T1 (de) 2009-03-15
CA2361496A1 (en) 2000-08-10
EP1146864B1 (en) 2009-03-04
PT1146864E (pt) 2009-03-20
ES2321908T3 (es) 2009-06-15
DE60041691D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
CY1108863T1 (el) Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη
HUP9800516A2 (hu) Gyógyszerforma kevéssé oldódó, bázisos gyógyszerhatóanyagok szabályzott felszabadítására
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
CA2601289A1 (en) Once-a-day oxycodone formulations
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
EA200200595A1 (ru) Лекарственная форма с высвобождением лекарства под действием гидрогеля
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
DE60038536D1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
EP0136103B1 (en) Amosulalol hydrochloride long acting formulations
EP0966966A3 (en) Nefazodone dosage form
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
BR0212155A (pt) Composição farmacêutica
US4738850A (en) Controlled release formulation and method
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
ES2186207T3 (es) Metodo para preparacion de formulaciones farmaceuticas.
IT1303753B1 (it) Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
EP0121901B1 (en) Ph independent controlled releasable tablets
DK1144420T3 (da) Sulfaterede phosphatidylinositoler, fremgangsmåde til fremstilling heraf og anvendelser heraf
CO4910116A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles